Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis.

Abstract

We conducted a systematic review and metaanalysis of randomized controlled trials to determine whether magnesium sulfate administered to women at risk of preterm delivery before 34 weeks of gestation may reduce the risk of cerebral palsy in their children. Six trials involving 4796 women and 5357 infants were included. Antenatal magnesium sulfate was associated with a significant reduction in the risk of cerebral palsy (relative risk [RR], 0.69; 95% confidence interval [CI], 0.55-0.88), moderate or severe cerebral palsy (RR, 0.64; 95% CI, 0.44-0.92), and substantial gross motor dysfunction (RR, 0.60; 95% CI, 0.43-0.83). There was no overall difference in the risk of total pediatric mortality (RR, 1.01; 95% CI, 0.89-1.14). Minor side effects were more frequent among women receiving magnesium sulfate. In conclusion, magnesium sulfate administered to women at risk of delivery before 34 weeks of gestation reduces the risk of cerebral palsy.

• Authors: Agustín Conde-Agudelo, Roberto Romero
• Journal: American journal of obstetrics and gynecology (Am J Obstet Gynecol) Vol. 200 Issue 6 Pg. 595-609 (Jun 2009) ISSN: 1097-6868 [Electronic] United States
• PMID: 19482113 (Publication Type: Journal Article, Meta-Analysis, Research Support, N.I.H., Intramural, Review, Systematic Review)

Chemical References

• Magnesium Sulfate

Topics

• Cerebral Palsy (prevention & control)
• Gestational Age
• Humans
• Infant, Newborn
• Infant, Premature, Diseases (prevention & control)
• Magnesium Sulfate (therapeutic use)
• Randomized Controlled Trials as Topic